ARTICLE | Emerging Company Profile
Adiso debuts with inflammatory pipeline, $60M from Morningside
Company seeking syndicate for series B
March 11, 2022 12:26 AM UTC
After several years of incubation in stealth, Morningside Ventures has launched Adiso with three potential first-in-class programs to treat inflammatory diseases.
Adiso Therapeutics Inc. made its public debut Thursday with sole investor Morningside Ventures having already invested $60 million in a series A round, which helped the company bring its first two programs into the clinic...